What question did this study set out to answer?

This study aims to uncover molecular drivers of immunosuppression in intrahepatic cholangiocarcinoma.

April 12, 2026Open Access

A Multi-omics Investigation Identifies TACC3 as a Driver of Immunosuppression in Intrahepatic Cholangiocarcinoma via Activation of the STAT3-PD-L1 Axis

Key Points

This study aims to uncover molecular drivers of immunosuppression in intrahepatic cholangiocarcinoma.
Utilized a multi-omics approach to analyze the tumor microenvironment.
Identified novel oncogenes associated with immune modulation.
Focus on the TACC3 gene and its role in activating immune checkpoints.
TACC3 was identified as a key driver of immunosuppression in ICC.
Activation of the STAT3-PD-L1 axis was linked to TACC3's effects.
Implications suggest that targeting TACC3 may enhance immunotherapy efficacy.

Abstract

The immunosuppressive tumor microenvironment (TME) limits immunotherapy efficacy in intrahepatic cholangiocarcinoma (ICC). Understanding the molecular drivers of this TME is essential for developing new therapies. This study aimed to identify novel oncogenes that modulate the immune landscape of ICC using a multi-omics approach.

Read Full Paperexternally

AIに質問

Bookmark

View Full Paper